| __timestamp | ADMA Biologics, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 159205000 |
| Thursday, January 1, 2015 | 4311461 | 174172000 |
| Friday, January 1, 2016 | 6360761 | 150976000 |
| Sunday, January 1, 2017 | 29164321 | 149380000 |
| Monday, January 1, 2018 | 42194635 | 187681000 |
| Tuesday, January 1, 2019 | 39504238 | 190434000 |
| Wednesday, January 1, 2020 | 61291426 | 206506000 |
| Friday, January 1, 2021 | 79769341 | 238029000 |
| Saturday, January 1, 2022 | 118814535 | 250127000 |
| Sunday, January 1, 2023 | 169273000 | 293274000 |
Unleashing the power of data
In the ever-evolving landscape of biopharmaceuticals, understanding cost structures is crucial. Over the past decade, ADMA Biologics, Inc. and Amphastar Pharmaceuticals, Inc. have showcased distinct trajectories in their cost of revenue. From 2014 to 2023, ADMA Biologics saw a staggering increase of over 4,400%, starting from a modest $3.7 million to a substantial $169 million. This growth reflects their aggressive expansion and scaling efforts.
Conversely, Amphastar Pharmaceuticals maintained a more stable yet significant growth, with costs rising by approximately 84% from $159 million to $293 million. This steady increase underscores their consistent market presence and operational efficiency.
These trends highlight the contrasting strategies of two industry players: ADMA's rapid scaling versus Amphastar's steady growth. As the biopharmaceutical sector continues to expand, these insights offer a glimpse into the financial strategies shaping the industry's future.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Viatris Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Amphastar Pharmaceuticals, Inc.
Dr. Reddy's Laboratories Limited vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Catalent, Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Catalent, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited
Comparing Cost of Revenue Efficiency: Amneal Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Comparison: Perrigo Company plc vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.